Publications

Lev, D. Prognosis factors in retroperitoneal Sarcomas. 2007. (In press).

Anaya DA, Lev DC, Pollock RE. The role of surgical margin status in retroperitoneal sarcomas. JSO 2007. (In press).

Blazer DG, Lazar AJ, Xing Y, Askew R, Feig BW, Pisters PW, Lev D, Pollock RE, Hunt K, Cormier. Outcomes in patients with clear cell sarcoma: Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with the data from the Surveillance, Epidemiology, and End Results Registry. Cancer 2009; 115:2971-2979.

Anaya DA, Lahat G, Wang X, Xiao L, Tuvin D, Pisters PW, Lev D, Pollock RE. Postoperative Nomogram for Survival in Patients with Retroperitoneal Sarcoma Treated with Curative Intent. Ann Oncol 2009; 249:1014-1022.

Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu Q, Lazar A, Bornmann W, McConkey DJ, Pollock RE, Lev DC.  Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 2009; 15:3472-3483.  [Article]

Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang W, Zhang W, McCutcheon E, Slopis JM, Lazar AJ, Pollock RE, Lev D.  Clinical, pathological and molecular variables predictive of malignant peripheral nerve sheath tumor (MPNST) outcome.  Ann Surg 2009; 249:1014-1022.  [Article]

Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Bornmann WG, Mills G, Lazar AJ, Pollock RE, Lev D.  Dual targeting of AKT and mTOR: a potential therapeutic approach for malignant peripheral nerve sheath tumor.  Mol Cancer Ther 2009; 15:3472-3483.  [Article]  

Anaya DA, Lahat G. Liu J, Xing Y, Cormier JN, Pisters PW, Lev DC, Pollock RE.  Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg 2009; 249: 137-142.  [Article]

Lahat G, Madewell JE, Anaya DE, Qiao W, Tuvin D, Benjamin RS, Lev D, Pollock RE.  CT scan-driven selection of treatment for retroperitoneal liposarcoma histological subtypes.  Cancer 2009; 115:1081-90.  [Article]

Anaya DA, Lahat G, Wang X, Xiao L, Tuvin D, Pisters PW, Lev DC, Pollock RE.  Establishing Prognosis in Retroperitoneal Sarcoma: A New Histology-Based Paradigm.  Ann Surg Oncol 2009; 16:667-675.  [Article]

Yang D, Wang S, Brooks C, Dong Z, Schoenlein P, Kumar V, Ouyang X, Xiong H, Lahat G, Hayes-Jordan A, Lazar A, Pollock R, Lev, D, Liu K.  IRF8 Sensitizes Soft Tissue Sarcoma Cells in Intrinsic Apoptosis Through Repression of FLIP Expression. Cancer Res 2009; 69: 1080-1088.  [Article]

Anaya DA, Lahat G, Liu J, Xing Y, Cormier JN, Pisters PW, Lev DC, Pollock RE.  Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgeon decision-making. Ann Surg 2009; 249:137-42.  [Article]

McAuliffe JC, Hunt KK, Lazar AJF, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC.  A randomized, phase II study of preoperative plus postoperative imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.  Ann Surg Oncol 2009; 16:910-9.  [Article]

McAuliffe JC, Wang W, Pavan GM, Pricl S, Yang D, Chen SS, Lazar A, Pollock RE, Trent JC. Unlucky number 13? differential effects of exon 13 mutation in GIST.  Molec Oncol 2009; 2:161-163.  [Article]

Lahat G, Alexander L, Xuemei W, Wei-Lien W, Quan-Sheng Z, Kelly H, Pollock RE, Lev D.  Increased VEGF-C expression is insufficient to induce lymphatic metastasis; insights from the study of human soft tissue sarcoma.  Clin Cancer Res 2009; 15:2637-2646.  [Article]

Yang J, Du X, Lazar A, Pollock RE, Hunt K, Chen K, Hao X, Trent J, Zhang W.  Genetic aberrations of gastrointestinal stromal tumors.  Cancer 2008; 113:1532-1543.

Lahat G, Tuvin D, Wei C, Anaya DA, Bekele BN, Lazar AJ, Pisters PW, Lev D, Pollock RE.  New perspectives for staging and prognosis in soft tissue sarcoma.  Ann Surg Onc 2008; 15:2739-2748.  [Article]

Jin Z, Lahat G, Korchin B, Nyugen T, Zhu Q, Wang X, Lazar A, Trent J, Pollock RE, Lev D. Midkine enhances human soft tissue sarcoma cell growth; a possible novel therapeutic target.  Clin Cancer Res 2008; 14:5033-5042.  [Article]

Wenhong R, Borys K, Lahat G, Wei C, Bolshakov S, Nguyen T, Merritt W, Dicker A, Lazar A, Sood A, Pollock RE, Lev D.  Combining VEGFR/EGFR blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma by targeting tumor cells and tumor associated endothelial cells.  Clin Cancer Res 2008; 14, 5466-5475.  [Article]  

Al-Refaie WB, Andtbacka RHI, Ensor J, Pisters PWT, Ellis TL, Hunt K, Cormier JN, Pollock RE, Feig B.  Lymphadenectomy for isolated lymph node metastasis from extremity soft tissue sarcomas.  Cancer 2008; 112:1821-6. [Article]

Lazar AJ, Tuvin D, Hajoibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, Warneke CL, Lopez-Terrada D, Pollock RE, Lev D. Specific mutations in the β-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoids tumors.  Am Jour Path 2008; 173:1518-1527. [Article]

Anaya DA, Lev D, Pollock RE. The role surgical margins in retroperitoneal sarcomas. J Surg Onc 2008; 98: 607-610. [Article] Kotiligam D, Lazar AJ, Pollock RE, Lev, D.  Desmoid tumor: a disease opportune for molecular insights.  Histol Histopathol 2008; 23:117-26. [Article]

Yang J, Du X, Chen K, Ylippa A, Lazar A, Trent J, Lev D, Pollock RE, Heo X, Hunt K, Zhang W. Genetic aberrations in soft tissue leiomyosarcoma.  Cancer Lett 2008; 275:1-8.  [Article]

Wenhong R, Korchin B, Zhu QS, Dicker A, Heymach J, Pollock RE, Lev D.  Epidermal growth factor receptor (EGFR) blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma (STS) cell growth in vitro and in vivo.  Clin Cancer Res 2008; 14:2785-2795. [Article]

Guadagnolo BA, Zagars GK, Ballo MT, Patel SR, Lewis VO, Benjamin RS, Pollock RE. Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy.  Int J Radiat Oncol Biol Phys 2008; 70:760-765. [Article]

Hajitou A, Lev DC, Hannay J, Korchin B, Staquicini FI, Soghomonyan S, Alauddin MM, Benjamin RB, Pollock RE, Gelovani JG, Pasqualini R, Arap W.  Predicting drug response in soft tissue sarcoma by targeting AAVP molecular-genetic imaging. PNAS 2008; 105:4471-6. [Article]

Zhu QS, Ren W, Korchin B, Lahat G, Dicker A, Lu Y, Mills G, Pollock RE, Lev D. Soft tissue sarcoma are highly sensitive to AKT blockade: a role for p53 independent up-regulation of GADD45? Cancer Res 2008; 68:2895-2903. [Article]

Lahat G, Anaya D, Wang X, Tuvin D, Lev D, Pollock RE.  Resectable well differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol 2008; 15:1585-1593. [Article]

Guadagnolo BA, Zagars GK, Ballo MT, Strom SS, Pollock RE, Benjamin RS.  Mortality after cure of soft-tissue sarcoma treated with conservation surgery and radiotherapy.  Cancer 2008; 113:411-8.  [Article]

Torres MA, Ballo MT, Butler CE, Feig BW, Cormier JN, Lewis VO, Pollock RE, Pisters PW, Zagars GK.  Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy.  Int J Radiat Oncol Biol Phys 2007; 67:1124-1129.  [Article]

Katz MH, Choi EA, Pollock RE.  Current concepts in multimodality therapy for retroperiotoneal sarcoma.  Expert Rev Anticancer Ther 2007; 7:159-168. [Article] Lin PP, Pino ED, Normand AN, Deavers MT, Cannon CP, Ballo MT, Pisters PW, Pollock RE, Lewis VO, Zagars GK, Yasko AW.  Periosteal margin in soft-tissue sarcoma.  Cancer 2007; 109:598-602.  [Article]

Ballo MT, Zagars GK, Pollock RE, Benajamin RS, Feig BW, Cormier JN, Hunt KK, Patel SR, Trent JC, Beddar S, Pisters PW.  Retroperitoneal soft tissue sarcoma: An analysis of radiation and surgical treatment.  Int J Radiat Oncol Biol Phys. 2007; 67:158-63. [Article]

Lim SJ, Cormier JN, Feig BW, Mansfield PF, Benjamin RS, Griffin JR, Chase JL, Pisters PW, Pollock RE, Hunt KK.  Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.  Ann Surg Oncol 2007; 14:2309-2318. [Article]

Guadagnolo BA, Zagars GK, Ballo MT, Patel SR, Lewis VO, Pisters PW, Benjamin RS, Pollock RE.  Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy.  Int J Radiat Oncol Biol Phys 2007; 15:1173-1180.  [Article]

Hannay J, Davis JJ, Yu D, et al. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Gene Therapy 2007; 14:671-681. [Article]

Hannay JA, Liu J, Bolshakov S, Pisters P, Yu D, Lazar A, Pollock RE, Lev D. Rad51 Over-expression Contributes to Chemoresistance in Human Soft Tissue Sarcoma Cells: a Role for p53/AP-2 Transcriptional regulation. Molecular Cancer Therapeutics  2007; 6:1650-1660. [Article]

Das P, Kotilingam D, Korchin J, Liu J YD, Lazar A, Pollock R, Lev D. A high prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer 2007; 109:2323-2333.  [Article]

Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, Lazar AA, Patel SR, Benjamin RS, RE Pollock. Optimizing Treatment of Desmoid Tumors. J Clin Oncol 2007; 25:1785-1791. [Article]

Schwartz B, Shoseyov O, Melinkova VO, McCarty M, Leslie M, Smirnoff P, Hu GF, Lev D, Bar-Eli M. ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis and metastasis. Cancer Research 2007; 67:5258-5266.  [Article]

Lazar AJF, Trent JC, Lev D, Sarcoma Molecular Testing:  Diagnosis and Prognosis. Curr Oncol Rep 2007; 9:309-315.  [Article]

Yang D, Thangaraju M, Browning D, Dong Z, Korchin B, Lev D, Ganapathy V, Liu K.  IFN regulatory factor 8 apoptosis in nonhemopoietic tumor cells via regulation of fas expression. J Immounol 2007; 179:4775-4782.  [Article]

Lazar AJ, Das P, Korchin B, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 2007; 13:7314-7321.  [Article]

Price, ND, Trent J, El-Naggar AK, Cogdell D, Taylor E, Hunt K, Pollock RE, Hood L, Shmulevich I, Zhang W.  Highly accurate two-gene diagnostic classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas.  PNAS 2007; 104:3414-3419. [Article]

Pisters PWT, Pollock RE, Lewis VO, Yasko AW, Cormier JN, Respondek PM, Feig BW, Hunt KK, Lin PP, Zagars G, Wei C, Ballo MT.  Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg 2007; 246:675-681. [Article]

Lazar A, Abruzzo LV, Pollock RE, Lee S, Czerniak B. Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. Arch Pathol Lab Med 2006; 130:1199-1207. [Article]

Kotilingam D, Lev DC, Lazar AJ, Pollock RE. Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin 2006; 56:282-291. [Article]

Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res 2006; 66 :8770-8778  [Article]

Liu J, Zhan M, Hannay JA, et al. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res 2006; 4:803-810. [Article]

Trent JC, Ramdas L, Dupart J, Hunt K, Macapinlac H, Taylor E, Hu L, Salvado A, Abbruzzese JL, Pollock RE, Benjamin RS, Zhang W. Early effects of Imatinib Mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.  Cancer 2006; 107:1898-908.  [Article]

Nykter M, Hunt KK, Pollock RE, El-Naggar AK, Taylor E, Shmulevich I, Ylli-Harja O, Zhang W.  Unsupervised analysis uncovers changes in histopathologic diagnosis in supervised genomic studies.  Technol Cancer Res Treat 2006; 5:177-182.  [Article]

Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D.  Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.  Cancer Res 2006; 66:8770-8778  [Article]

Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.  Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.  Ann Surg Oncol 2006; 14:14-24.

Zhan M, Yu D, Liu J, Glazer RI, Hannay J, Pollock RE. Transcriptional Repression of Protein Kinase C alpha via Sp1 by Wild Type p53 Is Involved in Inhibition of Multidrug Resistance 1 P-Glycoprotein Phosphorylation. J Biol Chem 2005; 280:4825-4833. [Article]

Hu M, Nicolson GL, Trent JC, 2nd, et al. Characterization of 11 human sarcoma cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors. Cancer 2002; 95:1569-1576. [Article]

Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res 2002; 62:2034-2042. [Article]

Shmulevich I, Hunt K, El-Naggar A, et al. Tumor specific gene expression profiles in human leiomyosarcoma: an evaluation of intratumor heterogeneity. Cancer 2002; 94:2069-2075. [Article] 

Zhan M, Yu D, Lang A, Li L, Pollock RE. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer 2001; 92:1556-1566. [Article]

Milas M, Yu D, Lang A, et al. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. Cancer Gene Ther 2000; 7:422-429.  [Article]

Zhang L, Yu D, Hu M, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000; 60:3655-3661. [Article]

Beech D, Pollock RE, Tsan R, Radinsky R. Epidermal growth factor receptor and insulin-like growth factor-I receptor expression and function in human soft-tissue sarcoma cells. Int J Oncol 1998; 12:329-336.

Yao J, Pollock RE, Lang A, et al. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res 1998; 4:1065-1070.  [Article]

Milas M, Yu D, Sun D, Pollock RE. Telomerase activity of sarcoma cell lines and fibroblasts is independent of p53 status. Clin Cancer Res 1998; 4:1573-1579. [Article]

Pollock R, Lang A, Ge T, Sun D, Tan M, Yu D. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clin Cancer Res 1998; 4:1985-1994. [Article]

Milas M, Feig B, Yu D, et al. Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. Clin Cancer Res 1997; 3:2197-2203. [Article]

Hu M, Pollock RE, Nicolson GL. Purification and characterization of human lung fibroblast motility-stimulating factor for human soft tissue sarcoma cells: identification as an NH2-terminal fragment of human fibronectin. Cancer Res 1997; 57:3577-3584. [Article]

Pollock RE, Lang A, Luo J, El-Naggar AK, Yu D. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene 1996; 12:2035-2039.